Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 19/20 | 0.72 |
| ▸ | NSD2 | O96028 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | BID | P55957 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.62 |
| ▸ | ASPH | Q12797 | 1/20 | 0.62 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.62 |
| ▸ | BAD | Q92934 | 1/20 | 0.62 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.62 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523173 | 0.91 | BCL2 (0.86) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL524070 | 0.86 | BCL2 (0.77) | BCL2BCL2L1MCL1BCL2L2 | |
| SCHEMBL18474331 | 0.85 | BCL2 (0.83) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL3501543 | 0.84 | BCL2 (1.00) | BCL2 | |
| SCHEMBL17627321 | 0.83 | BCL2 (0.82) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL19503727 | 0.81 | BCL2 (0.75) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL19424638 | 0.81 | BCL2 (0.68) | BCL2BCL2L1MCL1BCL2L2 | |
| SCHEMBL17627311 | 0.81 | BCL2 (0.64) | BCL2BCL2L1 | |
| SCHEMBL524049 | 0.81 | BCL2 (0.75) | BCL2 | |
| SCHEMBL21233544 | 0.80 | BCL2 (0.75) | BCL2NSD2ADORA3CYP2C9ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019161221-A2 | SELECTIVE BCL-2 INHIBITORS IN COMBINATION WITH AN ANTI-PD-1 OR AN ANTI-PD-L1 ANTIBODY FOR THE TREATMENT OF CANCERS | ABBVIE INC. (US) | 2019-08-22 | — | — | WO | disclosed |